JPWO2020144697A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020144697A5 JPWO2020144697A5 JP2021539922A JP2021539922A JPWO2020144697A5 JP WO2020144697 A5 JPWO2020144697 A5 JP WO2020144697A5 JP 2021539922 A JP2021539922 A JP 2021539922A JP 2021539922 A JP2021539922 A JP 2021539922A JP WO2020144697 A5 JPWO2020144697 A5 JP WO2020144697A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- antibody fragment
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 14
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 102000002356 Nectin Human genes 0.000 claims 3
- 108060005251 Nectin Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- -1 or carrier Substances 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213235A JP7788118B2 (ja) | 2019-01-13 | 2024-12-06 | ヒトネクチン－２に特異的な抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791808P | 2019-01-13 | 2019-01-13 | |
| US62/791,808 | 2019-01-13 | ||
| PCT/IL2020/050047 WO2020144697A1 (en) | 2019-01-13 | 2020-01-13 | Antibodies specific to human nectin-2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213235A Division JP7788118B2 (ja) | 2019-01-13 | 2024-12-06 | ヒトネクチン－２に特異的な抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519341A JP2022519341A (ja) | 2022-03-23 |
| JPWO2020144697A5 true JPWO2020144697A5 (enExample) | 2023-01-20 |
| JP7606706B2 JP7606706B2 (ja) | 2024-12-26 |
Family
ID=69701225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539922A Active JP7606706B2 (ja) | 2019-01-13 | 2020-01-13 | ヒトネクチン－２に特異的な抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220112283A1 (enExample) |
| EP (1) | EP3908372A1 (enExample) |
| JP (1) | JP7606706B2 (enExample) |
| KR (1) | KR20210117277A (enExample) |
| CN (2) | CN118878685A (enExample) |
| AU (1) | AU2020207664B2 (enExample) |
| CA (1) | CA3125962A1 (enExample) |
| IL (1) | IL284807B1 (enExample) |
| WO (1) | WO2020144697A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023226094A1 (en) | 2022-02-28 | 2024-09-12 | Nectin Therapeutics Ltd. | Humanized antibodies against nectin-2 and drug conjugates thereof |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| WO2024240899A1 (en) | 2023-05-23 | 2024-11-28 | Universite De Geneve | Dual targeting of psma and nectin2 in prostate cancer |
| WO2024240902A1 (en) | 2023-05-23 | 2024-11-28 | Fondazione per l'Istituto Oncologico di Ricerca | Monospecific and bispecific antibodies and antibody-drug conjugates targeting nectin2 (cd112) and psma |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1993015210A1 (en) | 1992-01-23 | 1993-08-05 | Merck Patent Gmbh | Monomeric and dimeric antibody-fragment fusion proteins |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JPH11508126A (ja) | 1995-05-23 | 1999-07-21 | モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー | 多量体タンパク質 |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| WO2007043635A1 (ja) * | 2005-10-07 | 2007-04-19 | Takeda Pharmaceutical Company Limited | 癌の予防・治療剤 |
| PE20081456A1 (es) * | 2006-10-06 | 2008-11-27 | Takeda Pharmaceutical | Anticuerpo monoclonal contra nectina 2 |
| KR101502501B1 (ko) | 2011-12-27 | 2015-03-13 | 주식회사 엘지화학 | 리튬 이차전지 및 그 제조방법 |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| ES2924071T3 (es) * | 2015-09-02 | 2022-10-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT) |
| CA2997179A1 (en) * | 2015-09-02 | 2017-03-09 | The Regents Of The Unversity Of Colorado, A Body Corporate | Compositions and methods for modulating t-cell mediated immune response |
| EA201890729A1 (ru) * | 2015-09-14 | 2018-09-28 | Элпайн Имьюн Сайнс, Инк. | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками |
| MX2018010445A (es) * | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US20190365806A1 (en) * | 2016-11-02 | 2019-12-05 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
-
2020
- 2020-01-13 EP EP20707330.5A patent/EP3908372A1/en active Pending
- 2020-01-13 CN CN202411054370.3A patent/CN118878685A/zh active Pending
- 2020-01-13 WO PCT/IL2020/050047 patent/WO2020144697A1/en not_active Ceased
- 2020-01-13 IL IL284807A patent/IL284807B1/en unknown
- 2020-01-13 AU AU2020207664A patent/AU2020207664B2/en active Active
- 2020-01-13 JP JP2021539922A patent/JP7606706B2/ja active Active
- 2020-01-13 US US17/421,885 patent/US20220112283A1/en active Pending
- 2020-01-13 CA CA3125962A patent/CA3125962A1/en active Pending
- 2020-01-13 CN CN202080009083.4A patent/CN113301954B/zh active Active
- 2020-01-13 KR KR1020217023368A patent/KR20210117277A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12077583B2 (en) | Antibodies specific to human NECTIN4 | |
| US11136392B2 (en) | PD-1 immune modulating agents | |
| RU2756275C2 (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| AU2018295119B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| JP2019511212A5 (enExample) | ||
| JPWO2019215728A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| US12110337B2 (en) | Anti-CD27 antibodies and uses thereof | |
| HUE035865T2 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| CN113301954B (zh) | 特异性针对人类连接蛋白-2的抗体 | |
| US11325976B2 (en) | Anti-programmed death-ligand 1 (PD-L1) antibodies and therapeutic uses thereof | |
| JPWO2020144697A5 (enExample) | ||
| JP2023517794A (ja) | 抗ｔｎｆｒ２抗体及びその使用 | |
| RU2021118587A (ru) | Антитела, специфичные в отношении нектина-2 человека | |
| RU2020133629A (ru) | Антитела, специфичные к нектину-4 человека | |
| HK40060175A (en) | Antibodies specific to human nectin-2 | |
| NZ745564B2 (en) | Antibodies specific to human poliovirus receptor (pvr) |